Cancer medicine · 2026
Diabetes Among Finnish Pancreatic Cancer Patients: Prevalence, Time Interval Between Diabetes and Cancer Diagnosis, and Overall Survival.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roosa Suitiala, Panu Aaltonen, Harri Mustonen, Malin Sund, Hanna Seppänen
Аннотация
INTRODUCTION: New-onset diabetes (NOD) potentially associated with pancreatic cancer (PC) requires further investigation to assess its potential as a tool for PC screening.
MATERIAL AND METHODS: In this longitudinal nationwide register study, which includes 14,712 PC patients and 18 years of follow-up time (2000-2018), we aimed to assess the prevalence of diabetes by using a large national registry. Survival was analyzed according to diabetes status and duration (long-term diabetes, i.e., DM diagnosed > 3 years prior to PC, NOD, i.e., DM diagnosed 0-3 years prior to PC, or DM diagnosed after PC diagnosis) and treatment status (curative intent vs. palliative) using multivariable Cox regression analysis.
RESULTS: Overall, 18% of PC patients had diabetes. The median time interval between DM and PC diagnoses was 4.8 months. In the multivariable Cox regression analysis, only DM diagnosed after PC was associated with worse survival, both in the palliative intent treatment group (HR 1.12, 95% CI 1.03-1.23, p = 0.011) and in the curative intent treatment group (HR 1.44, 95% CI 1.14-1.81, p = 0.002). Among patients diagnosed with diabetes prior to PC, neither long-term nor NOD significantly affected survival.
CONCLUSIONS: Most of the diabetic PC-patients have been diagnosed with DM within a close proximity of cancer diagnosis. The progression from diabetes to clinically detectable cancer seems to be rapid-less than 6 months. Given the aggressive nature of PC and the fact that NOD can be an early sign, screening may need to begin at the time of diabetes diagnosis. The fact that a DM diagnosis made after a PC diagnosis is associated with worse survival may suggest that pancreatic tumors that cause hyperglycemia are particularly aggressive.
MATERIAL AND METHODS: In this longitudinal nationwide register study, which includes 14,712 PC patients and 18 years of follow-up time (2000-2018), we aimed to assess the prevalence of diabetes by using a large national registry. Survival was analyzed according to diabetes status and duration (long-term diabetes, i.e., DM diagnosed > 3 years prior to PC, NOD, i.e., DM diagnosed 0-3 years prior to PC, or DM diagnosed after PC diagnosis) and treatment status (curative intent vs. palliative) using multivariable Cox regression analysis.
RESULTS: Overall, 18% of PC patients had diabetes. The median time interval between DM and PC diagnoses was 4.8 months. In the multivariable Cox regression analysis, only DM diagnosed after PC was associated with worse survival, both in the palliative intent treatment group (HR 1.12, 95% CI 1.03-1.23, p = 0.011) and in the curative intent treatment group (HR 1.44, 95% CI 1.14-1.81, p = 0.002). Among patients diagnosed with diabetes prior to PC, neither long-term nor NOD significantly affected survival.
CONCLUSIONS: Most of the diabetic PC-patients have been diagnosed with DM within a close proximity of cancer diagnosis. The progression from diabetes to clinically detectable cancer seems to be rapid-less than 6 months. Given the aggressive nature of PC and the fact that NOD can be an early sign, screening may need to begin at the time of diabetes diagnosis. The fact that a DM diagnosis made after a PC diagnosis is associated with worse survival may suggest that pancreatic tumors that cause hyperglycemia are particularly aggressive.